Release and activity of anti-TNFα therapeutics from injectable chitosan preparations for local drug delivery

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 90 B, Issue 1, 2009, Pages 319-326

  Shamji, Mohammed F ^a,b   Hwang, Priscilla ^a   Bullock, Robert W ^a   Adams, Samuel B ^c   Nettles, Dana L ^a   Setton, Lori A ^a,c  

^a Duke University   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chitosan; Curcumin; Drug delivery; Drug depot; Inflammation; Tumor necrosis factor alpha

Indexed keywords

ANTIBODIES; BIOASSAY; BIOCHEMISTRY; CHITIN; CHITOSAN; COAGULATION; DRUG DELIVERY; DRUG PRODUCTS; GELATION; GLYCOPROTEINS; LIGANDS; MACROPHAGES; PATHOLOGY; TOXICITY; TUMORS; TURBIDITY;

BOVINE SERUM ALBUMINS; CO-SOLUTIONS; CURCUMIN; CYTOKINE; DRUG DELIVERY VEHICLES; DRUG DEPOT; FIBROSARCOMA CELLS; GELATION TIME; GLYCEROPHOSPHATE; IN-VITRO; INFLAMMATION; KINETIC EFFECT; LOCAL DRUG DELIVERY; MOLECULAR SIZE; NATURAL PRODUCTS; PROTEIN LOADINGS; PROTEIN THERAPEUTICS; SLOW RELEASE; SMALL MOLECULES; SUSTAINED RELEASE; THERMOGELLING; TUMOR NECROSIS FACTOR ALPHA;

BODY FLUIDS;

CHITOSAN; CURCUMIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SYNTHESIS; IN VITRO STUDY; MOUSE; NONHUMAN; SUSTAINED DRUG RELEASE; TEMPERATURE MEASUREMENT;

ANIMALS; ANTIBODIES; CELL LINE, TUMOR; CHITOSAN; CURCUMIN; DRUG CARRIERS; GELS; KINETICS; MICE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650793131     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.31289     Document Type: Article

References (59)

1. Barbara JA, Smith WB, Gamble JR, Van Ostade X, Vandenabeele P, Tavernier J, Fiers W, Vadas MA, Lopez AF. Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. EMBO J 1994;13:843-850. (Pubitemid 2032538)
2. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004:CD003574.
3. Ghosh S. Anti-TNF therapy in Crohn's disease. Novartis Found Symp 2004;263:193-205; discussion 205-218.
4. Travers SB. Etanercept for Crohn's disease. N Engl J Med 2004;350:840; author reply 840.
5. Hoy SM, Scott LJ. Etanercept: A review of its use in the management of ankylosing spondylitis and psoriatic arthritis. Drugs 2007;67:2609-2633. (Pubitemid 350159169)
6. Wailoo A, Bansback N, Chilcott J. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: Costeffectiveness evidence and NICE guidance. Rheumatology (Oxford) 2008;47:119-120. (Pubitemid 351168216)
7. Adisen E, Karaca F, Gurer MA. When there is no single best biological agent: Psoriasis and psoriatic arthritis in the same patient responding to two different biological agents. Clin Exp Dermatol 2008;33:164-166. (Pubitemid 351197223)
8. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: Systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883-890.
9. Moreland LW. Tumor necrosis factor inhibitors: New options for treating rheumatoid arthritis. Isr Med Assoc J 2001;3:686-690. (Pubitemid 34044166)
10. Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: A pilot study. Ann Rheum Dis 2004;63:1120-1123. (Pubitemid 39120364)
11. Cottone M, Mocciaro F, Modesto I. Infliximab and ulcerative colitis. Expert Opin Biol Ther 2006;6:401-408.
12. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat 2004;15: 280-294. (Pubitemid 39423287)
13. Dinarello CA. Differences between anti-tumor necrosis factor- alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl 2005;74:40-47.
14. Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol Suppl 2005;74:35-39.
15. Keystone EC. Safety of biologic therapies-An update. J Rheumatol Suppl 2005;74:8-12.
16. Conti F, Priori R, Chimenti MS, Coari G, Annovazzi A, Valesini G, Signore A. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: A role for scintigraphy with 99mTc-infliximab. Arthritis Rheum 2005;52:1224-1226. (Pubitemid 40530130)
17. Johns Hopkins University. Efficacy of epidural etanercept in the treatment of sciatica. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine, US; 2006-Present. Available at http://www.clinicaltrials. gov/show/NCT00364572.
18. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-2900.
19. Hsu CH, Cheng AL. Clinical studies with curcumin. Adv Exp Med Biol 2007;595:471-480.
20. Thangapazham RL, Sharma A, Maheshwari RK. Beneficial role of curcumin in skin diseases. Adv Exp Med Biol 2007; 595:343-357.
21. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev 2002;54:3-12.
22. de Las Heras Alarcon C, Pennadam S, Alexander C. Stimuli responsive polymers for biomedical applications. Chem Soc Rev 2005;34:276-285. (Pubitemid 40444408)
23. Kost J, Langer R. Responsive polymeric delivery systems. Adv Drug Deliv Rev 2001;46:125-148.
24. Johnston TP, Punjabi MA, Froelich CJ. Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm Res 1992;9:425-434.
25. Clokie CM, Urist MR. Bone morphogenetic protein excipients: Comparative observations on poloxamer. Plast Reconstr Surg 2000;105:628-637.
26. Fults KA, Johnston TP. Sustained-release of urease from a poloxamer gel matrix. J Parenter Sci Technol 1990;44:58-65.
27. Palmer WK, Emeson EE, Johnston TP. Poloxamer 407- induced atherogenesis in the C57BL/6 mouse. Atherosclerosis 1998;136:115-123.
28. Wout ZG, Pec EA, Maggiore JA, Williams RH, Palicharla P, Johnston TP. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J Parenter Sci Technol 1992;46:192-200. (Pubitemid 23052584)
29. Li J, Li X, Ni X, Wang X, Li H, Leong KW. Self-assembled supramolecular hydrogels formed by biodegradable PEOPHB- PEO triblock copolymers and alpha-cyclodextrin for controlled drug delivery. Biomaterials 2006;27:4132-4140.
30. Chung HJ, Lee Y, Park TG. Thermo-sensitive and biodegradable hydrogels based on stereocomplexed Pluronic multiblock copolymers for controlled protein delivery. J Control Release 2008;127:22-30.
31. Brazel CS, Peppas NA. Pulsatile local delivery of thrombolytic and antithrombotic agents using poly(N-isopropylacrylamide- co-methacrylic acid) hydrogels. J Control Release 1996;39:57-64.
32. Kim YH, Bae YH, Kim SW. pH/temperature-sensitive polymers for macromolecular drug loading and release. J Control Release 1994;28:143-152.
33. Vihola H, Laukkanen A, Valtola L, Tenhu H, Hirvonen J. Cytotoxicity of thermosensitive polymers poly(N-isopropylacrylamide), poly(N-vinylcaprolactam) and amphiphilically modified poly(N-vinylcaprolactam). Biomaterials 2005;26: 3055-3064.
34. Bidwell GL III, Raucher D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol Cancer Ther 2005;4:1076-1085. (Pubitemid 41079101)
35. Massodi I, Bidwell GL III, Raucher D. Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J Control Release 2005;108:396-408. (Pubitemid 41608671)
36. Shamji MF, Betre H, Kraus VB, Chen J, Chilkoti A, Pichika R, Masuda K, Setton LA. Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: Sustained release of a local antiinflammatory therapeutic. Arthritis Rheum 2007;56:3650-3661. (Pubitemid 350100699)
37. Shamji MF, Chen J, Friedman AH, Richardson WJ, Chilkoti A, Setton LA. Synthesis and characterization of a thermally responsive tumor necrosis factor antagonist. J Controlled Release 2008;129:179-186.
38. Zentner GM, Rathi R, Shih C, McRea JC, Seo MH, Oh H, Rhee BG, Mestecky J, Moldoveanu Z, Morgan M, Steve Weitman. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 2001; 72:203-215. (Pubitemid 32522358)
39. Samlowski WE, McGregor JR, Jurek M, Baudys M, Zentner GM, Fowers KD. ReGel polymer-based delivery of interleukin- 2 as a cancer treatment. J Immunother 2006;29:524-535. (Pubitemid 44395277)
40. Miyazaki S, Suisha F, Kawasaki N, Shirakawa M, Yamatoya K, Attwood D. Thermally reversible xyloglucan gels as vehicles for rectal drug delivery. J Control Release 1998;56: 75-83. (Pubitemid 28511128)
41. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm 2001;229:29-36.
42. Takahashi A, Suzuki S, Kawasaki N, Kubo W, Miyazaki S, Loebenberg R, Bachynsky J, Attwood D. Percutaneous absorption of non-steroidal anti-inflammatory drugs from in situ gelling xyloglucan formulations in rats. Int J Pharm 2002;246:179-186. (Pubitemid 35247990)
43. Filion D, Lavertu M, Buschmann MD. Ionization and solubility of chitosan solutions related to thermosensitive chitosan/ glycerol-phosphate systems. Biomacromolecules 2007;8:3224-3234. (Pubitemid 350011646)
44. Ruel-Gariepy E, Chenite A, Chaput C, Guirguis S, Leroux J. Characterization of thermosensitive chitosan gels for the sustained delivery of drugs. Int J Pharm 2000;203:89-98. (Pubitemid 30627629)
45. Chenite A, Chaput C, Wang D, Combes C, Buschmann MD, Hoemann CD, Leroux JC, Atkinson BL, Binette F, Selmani A. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials 2000;21:2155-2161. (Pubitemid 30612386)
46. Bush JR, Madhu V, Laurencin CT, Balian G, Nair L. Thermosensitive chitosan as a matrix for the controlled delivery of biologically active molecules for bone repair. American Institute of Chemical Engineers Annual Meeting. Salt Lake City, UT; 2007.
47. Ruel-Gariepy E, Shive M, Bichara A, Berrada M, Le Garrec D, Chenite A, Leroux JC. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. Eur J Pharm Biopharm 2004;57:53-63. (Pubitemid 38058803)
48. Ganji F, Abdekhodaie MJ, Ramazani A. Gelation time and degradation rate of chitosan-based injectable hydrogel. J Sol- Gel Sci Technol 2007;42:47-53. (Pubitemid 46309210)
49. Kumar V, Lewis SA, Mutalik S, Shenoy DB, Venkatesh, Udupa N. Biodegradable microspheres of curcumin for treatment of inflammation. Indian J Physiol Pharmacol 2002;46: 209-217. (Pubitemid 34415120)
50. Truskey GA, Yuan F, Katz DF. Transport Phenomena in Biological Systems. Upper Saddle River, New Jersey: Prentice Hall; 2003. p 816.
51. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991;174:1483-1489.
52. Edwards CK III, Martin SW, Seely J, Kinstler O, Buckel S, Bendele AM, Ellen Cosenza M, Feige U, Kohno T. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev 2003;55:1315-1336. (Pubitemid 37464564)
53. Pan Ch J, Tang JJ, Weng YJ, Wang J, Huang N. Preparation, characterization and anticoagulation of curcumin-eluting controlled biodegradable coating stents. J Control Release 2006;116:42-49. (Pubitemid 44792298)
54. Yang X, Thomas DP, Zhang X, Culver BW, Alexander BM, Murdoch WJ, Rao MN, Tulis DA, Ren J, Sreejayan N. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol 2006;26:85-90. (Pubitemid 43732232)
55. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): A novel strategy for human cancer therapy. J Nanobiotechnol 2007;5:3. (Pubitemid 46705986)
56. Molinaro G, Leroux JC, Damas J, Adam A. Biocompatibility of thermosensitive chitosan-based hydrogels: An in vivo experimental approach to injectable biomaterials. Biomaterials 2002;23:2717-2722. (Pubitemid 34467049)
57. Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RS. Efficacy of chitosan microspheres for controlled intra-articular delivery of celecoxib in inflamed joints. J Pharm Pharmacol 2004;56:1091-1099. (Pubitemid 39207189)
58. Lu JX, Prudhommeaux F, Meunier A, Sedel L, Guillemin G. Effects of chitosan on rat knee cartilages. Biomaterials 1999;20:1937-1944. (Pubitemid 29421711)
59. Suh JK, Matthew HW. Application of chitosan-based polysaccharide biomaterials in cartilage tissue engineering: A review. Biomaterials 2000;21:2589-2598. (Pubitemid 30706207)